Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31583752 | 0.82 | P2RX7 (0.58) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL6458122 | 0.78 | RAB9A (0.41) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL6458112 | 0.78 | RAB9A (0.41) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL3165964 | 0.76 | ALDH1A1 (0.68) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL3108915 | 0.76 | RAB9A (0.49) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL3108907 | 0.76 | RAB9A (0.49) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL3115088 | 0.76 | RAB9A (0.49) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL6063992 | 0.75 | P2RX7 (0.54) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL4180056 | 0.75 | POLB (0.50) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| SCHEMBL13929047 | 0.75 | POLB (0.50) | CNR2CNR1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CNR2 52/4885CNR1 77/4885RAB9A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.